中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2011, Vol. 46 Issue (19) :1535-    DOI:
��ҩ���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
����HIV��Ⱦ����֬����л�ϰ�����ĸ���֬���������ҩ������Ī����
����������*
�й�ҽѧ��ѧԺ����Э��ҽԺҩ���ƣ����� 100730

Download: PDF (181KB)   HTML (0KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ 
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
�ؼ����� ��Ī����   ���������ͷ����Ӻϳ�������   ����֬������   HIV��Ⱦ��     
Abstract��
Keywords��   
�ո�����: 2012-01-01;
���ñ���:   
.����HIV��Ⱦ����֬����л�ϰ�����ĸ���֬���������ҩ������Ī����[J]  �й�ҩѧ��־, 2011,V46(19): 1535-
.[J]  Chinese Pharmaceutical Journal, 2011,V46(19): 1535-
��
[1] TRAYNOR K. FDA approves tesamorelin for HIV-related lipodystrophy[J]. Am J Health Syst Pharm�� 2010�� 67(24)�� 2082.[2] FDA. Label approved on 11/10/2010 (PDF) for EGRIFTA[EB/OL]. http��//www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf[3] FALUTZ J�� POTVIN D�� MAMPUTU J C�� et al. Effects of tesamorelin�� a growth hormone-releasing factor�� in HIV-infected patients with abdominal fat accumulation�� a randomized placebo-controlled trial with a safety extension[J]. J Acquir Immune Defic Syndr�� 2010�� 53(3)�� 311-322.[4] FALUTZ J�� ALLAS S�� MAMPUTU J C�� et al. Long-term safety and effects of tesamorelin�� a growth hormone-releasing factor analogue�� in HIV patients with abdominal fat accumulation[J]. Aids�� 2008�� 22(14)�� 1719-1728.[5] Side effects and complications. Tesamorelin-results from Phase III[J]. Treatment Update�� 2007�� 19(3)�� 6-7.
û���ҵ������������
Copyright 2010 by �й�ҩѧ��־